Evasion of complement-mediated lysis and complement C3 deposition are regulated by Francisella tularensis lipopolysaccharide O antigen

Journal of Immunology

Volumn 181, Issue 8, 2008, Pages 5568-5578

  Clay, Corey D ^a   Soni, Shilpa ^a   Gunn, John S ^a   Schlesinger, Larry S ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISERUM; BACTERIUM LIPOPOLYSACCHARIDE; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C7; COMPLEMENT FACTOR I; O ANTIGEN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL MEMBRANE; BACTERIAL STRAIN; BACTERIAL SURVIVAL; BACTERIOLYSIS; CARBOHYDRATE ANALYSIS; COMPLEMENT ACTIVATION; COMPLEMENT DEPOSITION; COMPLEMENT FIXATION; COMPLEMENT INHIBITION; CONTROLLED STUDY; FRANCISELLA TULARENSIS; HUMAN; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; BIOLOGICAL WARFARE; BIOLOGICAL WARFARE AGENT; CELL MEMBRANE; GENETICS; IMMUNOLOGY; MACROPHAGE; MICROBIOLOGY; MUTATION; PATHOGENICITY; PHAGOCYTOSIS; TULAREMIA;

BIOLOGICAL WARFARE AGENTS; BIOTERRORISM; CELL MEMBRANE; COMPLEMENT ACTIVATION; COMPLEMENT C1Q; COMPLEMENT C3; FRANCISELLA TULARENSIS; HUMANS; MACROPHAGES; MUTATION; O ANTIGENS; PHAGOCYTOSIS; TULAREMIA;

EID: 54049154653     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.181.8.5568     Document Type: Article

References (56)

1. Muller-Eberhard, H. J. 1988. Molecular organization and function of the complement system. Annu. Rev. Biochem. 57: 321-347. (Pubitemid 18171394)
2. Walport, M. J. 2001. Complement: first of two parts. N. Engl. J. Med. 344: 1058-1066.
3. Gros, P., F. J. Milder, and B. J. Janssen. 2008. Complement driven by conformational changes. Nat. Rev. Immunol. 8: 48-58.
4. Pangburn, M. K., and H. J. Muller-Eberhard. 1980. Relation of putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement. J. Exp. Med. 152: 1102-1114.
5. van Lookeren Campagne, M., C. Wiesmann, and E. J. Brown. 2007. Macrophage complement receptors and pathogen clearance. Cell. Microbiol. 9: 2095-2102. (Pubitemid 47250283)
6. Aderem, A., and D. M. Underhill. 1999. Mechanisms of phagocytosis in macrophages. Annu. Rev. Immunol. 17: 593-623.
7. Ellis, J., P. C. Oyston, M. Green, and R. W. Titball. 2002. Tularemia. Clin. Microbiol. Rev. 15: 631-646.
8. Oyston, P. C., A. Sjostedt, and R. W. Titball. 2004. Tularaemia: bioterrorism defence renews interest in Francisella tularensis. Nat. Rev. Microbiol. 2: 967-978.
9. Hollis, D. G., R. E. Weaver, A. G. Steigerwalt, J. D. Wenger, C. W. Moss, and D. J. Brenner. 1989. Francisella philomiragia comb. nov. (formerly Yersinia philomiragia) and Francisella tularensis biogroup novicida (formerly Francisella novicida) associated with human disease. J. Clin. Microbiol. 27: 1601-1608.
10. Eigelsbach, H. T., W. Braun, and R. D. Herring. 1951. Studies on the variation of Bacterium tularense. J. Bacteriol. 61: 557-569.
11. Cowley, S. C., S. V. Myltseva, and F. E. Nano. 1996. Phase variation in Francisella tularensis affecting intracellular growth, lipopolysaccharide antigenicity and nitric oxide production. Mol. Microbiol. 20: 867-874.
12. Hartley, G., R. Taylor, J. Prior, S. Newstead, P. G. Hitchen, H. R. Morris, A. Dell, and R. W. Titball. 2006. Grey variants of the live vaccine strain of Francisella tularensis lack lipopolysaccharide O-antigen, show reduced ability to survive in macrophages and do not induce protective immunity in mice. Vaccine 24: 989-996. (Pubitemid 43185317)
13. Dennis, D. T., T. V. Inglesby, D. A. Henderson, J. G. Bartlett, M. S. Ascher, E. Eitzen, A. D. Fine, A. M. Friedlander, J. Hauer, M. Layton, et al. 2001. Tularemia as a biological weapon: medical and public health management. J. Am. Med. Assoc. 285: 2763-2773. (Pubitemid 32525374)
14. Heymann, D. L. 2000. Tularemia. In Control of Communicable Diseases Manual. J. Chin, ed. American Public Health Association, Washington, DC, pp. 532-535.
15. Cross, J. T., and R. L. Penn. 2000. Francisella tularensis (tularemia). In Principles and Practice of Infectious Diseases. G. L. Mandell, J. Bennett, and R. Dolin, eds. Churchill Livingstone, Philadelphia, pp. 2393-2402.
16. McCrumb, F. R. 1961. Aerosol infection of man with Pasteurella tularensis. Bacteriol. Rev. 25: 262-267.
17. Fortier, A. H., S. J. Green, T. Polsinelli, T. R. Jones, R. M. Crawford, D. A. Leiby, K. L. Elkins, M. S. Meltzer, and C. A. Nacy. 1994. Life and death of an intracellular pathogen: Francisella tularensis and the macrophage. Immunol. Ser. 60: 349-361.
18. Balagopal, A., A. S. MacFarlane, N. Mohapatra, S. Soni, J. S. Gunn, and L. S. Schlesinger. 2006. Characterization of the receptor-ligand pathways important for entry and survival of Francisella tularensis in human macrophages. Infect. Immun. 74: 5114-5125. (Pubitemid 44300429)
19. Clemens, D. L., B. Y. Lee, and M. A. Horwitz. 2005. Francisella tularensis enters macrophages via a novel process involving pseudopod loops. Infect. Immun. 73: 5892-5902.
20. Ben Nasr, A., J. Haithcoat, J. E. Masterson, J. S. Gunn, T. Eaves-Pyles, and G. R. Klimpel. 2006. Critical role for serum opsonins and complement receptors CR3 (CD11b/CD18) and CR4 (CD11c/CD18) in phagocytosis of Francisella tularensis by human dendritic cells (DC): uptake of Francisella leads to activation of immature DC and intracellular survival of the bacteria. J. Leukocyte Biol. 80: 774-786.
21. Sandstrom, G., S. Lofgren, and A. Tarnvik. 1988. A capsule-deficient mutant of Francisella tularensis LVS exhibits enhanced sensitivity to killing by serum but diminished sensitivity to killing by polymorphonuclear leukocytes. Infect. Immun. 56: 1194-1202. (Pubitemid 18123739)
22. Maier, T. M., M. S. Casey, R. H. Becker, C. W. Dorsey, E. M. Glass, N. Maltsev, T. C. Zahrt, and D. W. Frank. 2007. Identification of Francisella tularensis Himar1-based transposon mutants defective for replication in macrophages. Infect. Immun. 75: 5376-5389.
23. Horwitz, M. A., and S. C. Silverstein. 1980. Influence of the Escherichia coli capsule on complement fixation and on phagocytosis and killing by human phagocytes. J. Clin. Invest. 65: 82-94.
24. Berger, M. 1990. Third component of human complement: C3. Methods Enzymol. 184: 619-628.
25. Tsai, C. M., and C. E. Frasch. 1982. A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels. Anal. Biochem. 119: 115-119.
26. Joiner, K. A. 1988. Complement evasion by bacteria and parasites. Annu. Rev. Microbiol. 42: 201-230.
27. James, K. 1982. Complement: activation, consequences, and control. Am. J. Med. Technol. 48: 735-742.
28. Forestal, C. A., M. Malik, S. V. Catlett, A. G. Savitt, J. L. Benach, T. J. Sellati, and M. B. Furie. 2007. Francisella tularensis has a significant extracellular phase in infected mice. J. Infect. Dis. 196: 134-137.
29. White, J. D., J. R. Rooney, P. A. Prickett, E. B. Darrenbacher, C. W. Beard, and W. R. Griffith. 1964. Pathogenesis of experimental respiratory tularemia in monkeys. J. Infect. Dis. 114: 277-283.
30. Bolger, M. S., D. S. Ross, H. Jiang, M. M. Frank, A. J. Ghio, D. A. Schwartz, and J. R. Wright. 2007. Complement levels and activity in the normal and LPSinjured lung. Am. J. Physiol. 292: L748-L759.
31. Cole, F. S., W. J. Matthews, Jr., T. H. Rossing, D. J. Gash, N. A. Lichtenberg, and J. E. Pennington. 1983. Complement biosynthesis by human bronchoalveolar macrophages. Clin. Immunol. Immunopathol. 27: 153-159.
32. Strunk, R. C., D. M. Eidlen, and R. J. Mason. 1988. Pulmonary alveolar type II epithelial cells synthesize and secrete proteins of the classical and alternative complement pathways. J. Clin. Invest. 81: 1419-1426.
33. Ferguson, J. S., J. J. Weis, J. L. Martin, and L. S. Schlesinger. 2004. Complement protein C3 binding to Mycobacterium tuberculosis is initiated by the classical pathway in human bronchoalveolar lavage fluid. Infect. Immun. 72: 2564-2573.
34. Watford, W. T., A. J. Ghio, and J. R. Wright. 2000. Complement-mediated host defense in the lung. Am. J. Physiol. 279: L790-L798.
35. Figueroa, J. E., and P. Densen. 1991. Infectious diseases associated with complement deficiencies. Clin. Microbiol. Rev. 4: 359-395.
36. Malik, M., C. S. Bakshi, K. McCabe, S. V. Catlett, A. Shah, R. Singh, P. L. Jackson, A. Gaggar, D. W. Metzger, J. A. Melendez, et al. 2007. Matrix metalloproteinase 9 activity enhances host susceptibility to pulmonary infection with type A and B strains of Francisella tularensis. J. Immunol. 178: 1013-1020. (Pubitemid 46095174)
37. Underhill, D. M., and A. Ozinsky. 2002. Phagocytosis of microbes: complexity in action. Annu. Rev. Immunol. 20: 825-852.
38. McLendon, M. K., M. A. Apicella, and L. A. Allen. 2006. Francisella tularensis: taxonomy, genetics, and immunopathogenesis of a potential agent of biowarfare. Annu. Rev. Microbiol. 60: 167-185.
39. Reckseidler-Zenteno, S. L., R. DeVinney, and D. E. Woods. 2005. The capsular polysaccharide of Burkholderia pseudomallei contributes to survival in serum by reducing complement factor C3b deposition. Infect. Immun. 73: 1106-1115.
40. Stevens, P., S. N. Huang, W. D. Welch, and L. S. Young. 1978. Restricted complement activation by Escherichia coli with the K-1 capsular serotype: a possible role in pathogenicity. J. Immunol. 121: 2174-2180. (Pubitemid 9075180)
41. Cunnion, K. M., J. C. Lee, and M. M. Frank. 2001. Capsule production and growth phase influence binding of complement to Staphylococcus aureus. Infect. Immun. 69: 6796-6803.
42. Hood, A. M. 1977. Virulence factors of Francisella tularensis. J. Hyg. 79: 47-60.
43. Su, J., J. Yang, D. Zhao, T. H. Kawula, J. A. Banas, and J. R. Zhang. 2007. Genome-wide identification of Francisella tularensis virulence determinants. Infect. Immun. 75: 3089-3101. (Pubitemid 46870195)
44. Cherwonogrodzky, J. W., M. H. Knodel, and M. R. Spence. 1994. Increased encapsulation and virulence of Francisella tularensis live vaccine strain (LVS) by subculturing on synthetic medium. Vaccine 12: 773-775.
45. Geisbert, T. W., P. B. Jahrling, and J. W. Ezzell, Jr. 1993. Use of immunoelectron microscopy to demonstrate Francisella tularensis. J. Clin. Microbiol. 31: 1936-1939.
46. Raynaud, C., K. L. Meibom, M. A. Lety, I. Dubail, T. Candela, E. Frapy, and A. Charbit. 2007. Role of the wbt locus of Francisella tularensis in lipopolysaccharide O-antigen biogenesis and pathogenicity. Infect. Immun. 75: 536-541. (Pubitemid 46047934)
47. Sorokin, V. M., N. V. Pavlovich, and L. A. Prozorova. 1996. Francisella tularensis resistance to bactericidal action of normal human serum. FEMS Immunol. Med. Microbiol. 13: 249-252. (Pubitemid 26135307)
48. Gunn, J. S., and R. K. Ernst. 2007. The structure and function of Francisella lipopolysaccharide. Ann. NY Acad. Sci. 1105: 202-218.
49. Prior, J. L., R. G. Prior, P. G. Hitchen, H. Diaper, K. F. Griffin, H. R. Morris, A. Dell, and R. W. Titball. 2003. Characterization of the O antigen gene cluster and structural analysis of the O antigen of Francisella tularensis subsp. tularensis. J. Med. Microbiol. 52: 845-851.
50. Vinogradov, E., W. J. Conlan, J. S. Gunn, and M. B. Perry. 2004. Characterization of the lipopolysaccharide O-antigen of Francisella novicida (U112). Carbohydr. Res. 339: 649-654. (Pubitemid 38167663)
51. Cowley, S. C., C. J. Gray, and F. E. Nano. 2000. Isolation and characterization of Francisella novicida mutants defective in lipopolysaccharide biosynthesis. FEMS Microb. Lett. 182: 63-67. (Pubitemid 30001566)
52. Sebastian, S., S. T. Dillon, J. G. Lynch, L. T. Blalock, E. Balon, K. T. Lee, L. E. Comstock, J. W. Conlan, E. J. Rubin, A. O. Tzianabos, and D. L. Kasper. 2007. A defined O-antigen polysaccharide mutant of Francisella tularensis live vaccine strain has attenuated virulence while retaining its protective capacity. Infect. Immun. 75: 2591-2602. (Pubitemid 46744351)
53. Li, J., C. Ryder, M. Mandal, F. Ahmed, P. Azadi, D. S. Snyder, R. D. Pechous, T. Zahrt, and T. J. Inzana. 2007. Attenuation and protective efficacy of an O-antigen-deficient mutant of Francisella tularensis LVS. Microbiology 153: 3141-3153. (Pubitemid 47517074)
54. Ben Nasr, A., and G. R. Klimpel. 2008. Subversion of complement activation at the bacterial surface promotes serum resistance and opsonophagocytosis of Francisella tularensis. J. Leukocyte Biol. 84: 77-85.
55. Kraiczy, P., and R. Wurzner. 2006. Complement escape of human pathogenic bacteria by acquisition of complement regulators. Mol. Immunol. 43: 31-44. (Pubitemid 41024919)
56. Lambris, J. D., D. Ricklin, and B. V. Geisbrecht. 2008. Complement evasion by human pathogens. Nat. Rev. Microbiol. 6: 132-142.